Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects

Obesity Clinical Trial

Official title:

A Phase 2, Randomized, Double‑Blind, Placebo‑Controlled, Multicenter Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00444561
• Other study ID #: 137-160
• Status: Completed
• Phase: Phase 2
• First received: March 6, 2007
• Last updated: June 10, 2015
• Start date: August 2004
• Est. completion date: May 2005

Study information

• Verified date: May 2015
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This exploratory study is designed to evaluate various pharmacodynamic effects of subcutaneously (SC) infused or injected pramlintide in obese, nondiabetic male and postmenopausal female (not on hormone replacement therapy) subjects. The study will also assess the safety and tolerability of pramlintide administered by SC infusion or injection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 184
• Est. completion date: May 2005
• Est. primary completion date: May 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 25 Years to 60 Years

Eligibility

Inclusion Criteria:

• Is <6'3" (190.5 cm) tall and weighs <300 lb (~136.3 kg)

• Is obese with a body mass index (BMI) >=30 kg/m^2 to <=45 kg/m^2 and with a history consistent with progressive weight gain and development of obesity not secondary to drastic or traumatic initiating events (e.g., excessive weight gain due to cessation of smoking)

• Is a nonsmoker (never smoked or has not smoked for at least 2 years)

• Does not have a clinical diagnosis of diabetes

• Has not had a major change in daily physical activity within 2 months prior to study start (e.g., initiation of an exercise program)

• Usually consumes three major meals (morning, midday, and evening) each day and rarely (less than once a week) wakes up to eat during the night

Exclusion Criteria:

• Is currently enrolled in a weight loss program or plans to enroll in a weight loss or exercise program within the next 3 months

• Is currently treated or expected to require or undergo treatment or has been treated within 2 months before screening with medications that are excluded:

• Over the counter antiobesity agents including herbal supplements or prescription antiobesity agents approved for the long-term (including orlistat [Xenical] and sibutramine [Meridia]) and the short-term (including phentermine [Adipex-P, Celltech, Pro-Fast SA, Pro-Fast SR, Fastin, Oby trim, Zantryl, Teramine, Phentride, Phentercot, Obephen, Oby-cap], mazindol [Sanorex and Mazanor], methamphetamine [Desoxyn], diethylpropion [Tenuate and Tenuate Dospan], phendimetrazine [Bontril, Prelu-2, Melfiat 105, Unicelles, X-Trozine, Plegine, Adipost, Obezine, Phendiet-105, PT 105] and benzphetamine [Didrex]) treatment of obesity

• Systemic steroids by oral, intravenous, or intramuscular route or potent topical steroids that are known to result in high systemic absorption

• Alpha- or Beta-Blockers, centrally acting sympathicolytic or sympathicomimetic agents, reserpin, guanethidine, etc.

• Psychotropic medications (e.g., tricyclic antidepressants, monoamine oxidase [MAO] inhibitors, selective serotonin reuptake inhibitors [SSRIs], neuroleptics, lithium, and benzodiazepines)

• Hypnotic-sedative medications or medications that may affect sleeping behavior including medications containing caffeine

• Drugs that directly affect gastrointestinal motility, including but not limited to: metoclopramide (Reglan®) and cisapride (Propulsid®); and macrolide antibiotics such as erythromycin and newer derivatives

• Has received any investigational drug within 3 months before study start

• Has participated previously in a study using pramlintide

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Obesity
• Overweight

Intervention

Drug:
• pramlintide acetate
Clear, colorless, sterile solution for SC administration

Locations

Country	Name	City	State
United States	Research Site	Baton Rouge	Louisiana
United States	Research Site	Butte	Montana
United States	Research Site	Chula Vista	California
United States	Research Site	DeLand	Florida
United States	Research Site	Fort Lauderdale	Florida
United States	Research Site	Lexington	Kentucky
United States	Research Site	Long Beach	California
United States	Research Site	New Orleans	Louisiana
United States	Research Site	San Antonio	Texas
United States	Research Site	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate various pharmacodynamic effects (including effects on body weight, food intake, and other parameters) of subcutaneously (SC) infused or injected pramlintide in obese subjects.		73 Days
Secondary	To evaluate the safety and tolerability of SC infused or injected pramlintide in obese subjects.		73 Days